GlassScriptPhysician profile
Yi-Tsung Lu
NPI 1649685504
$2,273.08
in general payments reported to CMS, 2019-2025
16 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,792 · 2020: $249 · 2023: $113 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $383.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $346.64 | 2019-2023 | Calquence |
| Ipsen Biopharmaceuticals, INC | $267.58 | 2019-2020 | |
| Genentech USA, INC. | $168.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $147.57 | 2019 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2019 | |
| Exelixis INC. | $125.00 | 2019 | |
| Puma Biotechnology, INC. | $124.95 | 2019 | |
| Btg International INC. | $119.76 | 2025 | Voraxaze |
| Amgen INC. | $100.99 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.42 | 2019-2020 | |
| Incyte Corporation | $75.99 | 2019 | |
| Janssen Research & Development, LLC | $46.10 | 2019 | |
| Genzyme Corporation | $22.37 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $22.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi-Tsung Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.